Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Core Viewpoint - Lisata Therapeutics has regained full development rights to certepetide in the Greater China region following the mutual termination of its agreement with Qilu Pharmaceutical, allowing the company to pursue its own development and commercialization strategies for this product [1][2]. Group 1: Agreement Termination - The February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical has been mutually terminated, resulting in all rights reverting to Lisata [1]. - Qilu will continue to fulfill its obligations related to the ongoing Phase 2 clinical study of certepetide in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma [3]. Group 2: Product Overview - Certepetide is an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors by activating a novel uptake pathway [4]. - The product has shown favorable safety and tolerability in clinical trials and has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers [4]. Group 3: Company Background - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and has established partnerships based on its CendR Platform technology [5]. - The company anticipates announcing several milestones over the next 1.5 years and believes its capital will support operations into the first quarter of 2027 [5].